Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (February 2025)
23 slides from Revelation Biosciences's investor presentation, Feb 11, 2025
Slide 1: Rebalancing inflammation to optimize health
Rebalancing inflammation to optimize health NASDAQ: REVB www.revbiosciences.com
Slide 2: Forward-looking statements
This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe
Slide 3: Gemini Platform
Gemini™ Platform 1 Gemini is our proprietary formulation platform intended to optimize PHAD’s route of administration appropriate for a specific condition 2 Initially focused on acute indications to leverage existing IND and acute clinical data
Slide 4: Gemini Has Large Market Potential
Gemini Has Large Market Potential AKI $6 Billion 5M total patients CKD $9.25 Billion 37M total patients PSI $3.125 Billion 6.25M total patients MARKET $18+ Billion POTENTIAL
Slide 5: How Gemini Works
How Gemini Works Reduced Preconditioned inflammation Recovery Gemini No Gemini No Recovery ——_—_—i to Longer Recovery r~ Normal State Significant / \ inflammation REVELATION /— \ - BIOSCIENCES NS
Slide 6: GEM-AKI and GEM-CKD: Gemini For Acute Kidney Injury and Chronic Kidney Disease
GEM-AKI and GEM-CKD Gemini For Acute Kidney Injury and Chronic Kidney Disease 6
Slide 7: Positive Phase 1 Clinical Results in Healthy Volunteers
Gemini was well tolerated, induced trained immunity with significant anti-inflammatory cytokine up regulation Gemini stimulated a robust significant induction of IL-1RA and IL-10 Phase 1 biomarker data consistent with preclinical animal model data Positive Phase 1 Clinical Results in Healthy Volunte
Slide 8: PRIME Phase 1b Clinical Study in CKD Patients
PRIME – PRotective IMmunostimulatory Evaluation A Phase 1b, Randomized, Placebo Controlled, Single Blind, Single-Ascending Dose in Stage 3 and Stage 4 CKD Patients Design Single dose, dose escalation 5 cohorts, 8 subjects per cohort 1:4 placebo vs drug (up to 40 patients) Follow for 7 days Readouts
Slide 9: GEM-PSI: Gemini for Post-Surgical Infection
GEM-PSI Gemini for Post-Surgical Infection 9
Slide 10: PHAD Pretreatment Protects Against Severe Systemic Infection
Work with Vanderbilt shows faster clearance and increased survival from systemic infection after treatment with PHAD Similar data for gram negative bacteria DOI: 10.1097/CCM.0000000000003967 PHAD Pretreatment Protects Against Severe Systemic Infection S. Aureus Clearance Lung Kidney Spleen CFU/g CFU
Slide 11: Financial Overview
Financial Overview 2 REVELATION / BIOSCIENCES a Ss.
Slide 12: Relevant Market Information
Relevant Market Information (as of 2/4/2025) Stock Price $4.46 Common Stock Outstanding 905,228 Market Cap $4.0M Fully Diluted Share Count 1,411,290 Financial Summary Balance Sheet and P&L (as of 12/12/2024) Cash $7.1 M Stockholders’ Equity $6.0 M Quarterly Burn Rate $2.2 M
Slide 13: Why You Should Invest in REVB
Enormous market potential ($18+ Billion) Experienced Management with multiple FDA approvals (8 approvals) Rapidly derisking the Gemini platform Product candidates that can significantly help many people Why You Should Invest in REVB
Slide 14: Thank You!
Thank You! For more information, please visit www.revbiosciences.com 14
Slide 15: Supplemental Information
Supplemental Information 15
Slide 16: How Gemini Works
Gemini stimulates TLR4 via the TRIF pathway which is the anti-inflammatory pathway Gemini TLR4 stimulation trains the immune cells to tolerate future stress via an anti-inflammatory response The anti-inflammatory response is beneficial for many diseases/conditions including AKI, CKD, PSI and many mo
Slide 17: Gemini Induces TLR4 Innate Immune Response
Gemini administration in healthy animals resulted in Neutrophils migration from circulation with subsequent rebound Upregulation of IL-10 and IL-1RA, anti-inflammatory cytokines critical to resolution of inflammation Upregulation of IL-6, a necessary first step in the establishment of trained immuni
Slide 18: Gemini Treatment Reduces Fibrosis in an AKI Model
Treatment with Gemini resulted in a significant dose-dependent reduction in fibrosis 1DOI: 10.1093/ndt/15.suppl_6.72 Gemini Treatment Reduces Fibrosis in an AKI Model
Slide 19: Gemini Treatment Reduces Fibrosis in a CKD Model
Reduction in fibrosis driven by reduced pro-inflammatory cytokines and increased anti-inflammatory cytokines TGF-β is pro-fibrotic and is directly linked to the propagation of fibrosis1 IL-10 is a key driver for the reduction and resolution of inflammation NGAL is an important defense for preventing
Slide 20: Gemini's Anti-Inflammatory Effect in an Ischemia/Reperfusion Model
Pretreatment with Gemini significantly reduced multiple markers of local inflammation at 24 and/or 72 hours in urine Pretreatment with Gemini significantly reduced CRP at 72 hours in serum Pretreatment with Gemini also significantly reduced markers of cellular inflammation as observed via reduced ne
Slide 21: Gemini Reduces AKI in an Ischemia/Reperfusion Model
Kidney Function at 24 and 72 hours Kidney Injury at 72 hours Gemini pretreatment significantly preserved kidney function with return to base line faster relative to untreated control animals Additional renal function findings included improved creatinine clearance and excretion relative to the untre
Slide 22: PHAD Reduces AKI in a Unilateral Ischemia/Reperfusion Model
PHAD Reduces AKI in a Unilateral Ischemia/Reperfusion Model DOI: 10.1152/ajprenal.00248.2022 Vanderbilt University ran the same preclinical model and got similar results
Slide 23: PHAD Reduces AKI in a Bilateral Ischemia/Reperfusion Model
PHAD Reduces AKI in a Bilateral Ischemia/Reperfusion Model DOI: 10.1152/ajprenal.00248.2022 Vanderbilt University ran the same preclinical model and got similar results
Revelation Biosciences — Investor Presentation (February 2025) on 6ix